Bone Biologics (BBLG) Non Operating Income (2014 - 2026)
Bone Biologics (BBLG) posted quarterly Non Operating Income of $48462.0 for Q4 2025, up 45.87% year-over-year from $33223.0 in Q4 2024, and little changed quarter-over-quarter from $48537.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Non Operating Income (2014 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Non Operating Income for 9 consecutive years, with $48462.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non Operating Income rose 45.87% year-over-year to $48462.0; the TTM figure through Dec 2025 stood at $125949.0 (up 18.0% YoY), while the FY2025 annual figure was $125951.0, up 18.0% from the prior year.
- Non Operating Income steadied at $48462.0 in Q4 2025 per BBLG's latest filing, from $48537.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.3 million in Q2 2023 and bottomed at -$562362.0 in Q1 2023.
- Historically, Non Operating Income has averaged $59355.1 across 3 years, with a median of $29577.5 in 2024.
- Annual changes were most pronounced in 2024 — Non Operating Income sank 97.96% — and 2025, when it soared 384.45%.
- Bone Biologics' Non Operating Income stood at -$389877.0 in 2023, then jumped by 108.52% to $33223.0 in 2024, then surged by 45.87% to $48462.0 in 2025.
- Business Quant data shows BBLG's Non Operating Income at $48462.0 in Q4 2025, $48537.0 in Q3 2025, and $7556.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | - |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | 34,404.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34,404.00 |
| Dec 31, 2025 | 48,462.00 |
| Sep 30, 2025 | 48,537.00 |
| Jun 30, 2025 | 7,556.00 |
| Mar 31, 2025 | 21,394.00 |
| Dec 31, 2024 | 33,223.00 |
| Sep 30, 2024 | 10,019.00 |
| Jun 30, 2024 | 25,932.00 |
| Mar 31, 2024 | 37,566.00 |
| Dec 31, 2023 | -389,877.00 |
| Sep 30, 2023 | 161,181.00 |
| Jun 30, 2023 | 1.27 Mn |
| Mar 31, 2023 | -562,362.00 |
| Dec 31, 2019 | -253,554.00 |
| Sep 30, 2019 | -260,070.00 |
| Dec 31, 2018 | -231,760.00 |
| Sep 30, 2018 | -646,528.00 |
| Dec 31, 2017 | -1.46 Mn |
| Sep 30, 2017 | -1.24 Mn |
| Jun 30, 2017 | -957,062.00 |